Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2024 | Comparing different assays for detecting AD plasma biomarkers

Gemma Salvadó • 20 Aug 2024
AAIC 2024
Alzheimer’s Disease Dementia

Gemma Salvadó, PhD, Lund University, Lund, Sweden, comments on the performance of different assays for detecting plasma biomarkers of Alzheimer’s disease (AD). She mentions studies showing that mass spectrometry-based methods perform better than immunoassays, although the difference is small. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2024 in Philadelphia, PA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Gemma Salvadó

The potential clinical utility of the novel p-tau205 biomarker in Alzheimer's disease
3:00
The potential clinical utility of the novel p-tau205 biomarker in Alzheimer's disease
Gemma Salvadó • 12 Dec 2025
The biological staging of AD using blood-based biomarkers: combining p-tau217 and MTBR-tau243
2:41
The biological staging of AD using blood-based biomarkers: combining p-tau217 and MTBR-tau243
Gemma Salvadó • 12 Dec 2025
The potential of plasma biomarkers in assessing preclinical Alzheimer's disease
3:25
The potential of plasma biomarkers in assessing preclinical Alzheimer's disease
Gemma Salvadó • 12 Dec 2025
Using plasma ptau217 to select cognitively unimpaired participants for AD prevention trials
4:34
Using plasma ptau217 to select cognitively unimpaired participants for AD prevention trials
Gemma Salvadó • 20 Aug 2024

Related Videos

Shingles vaccination is associated with a reduced risk of new dementia diagnoses
4:49
Shingles vaccination is associated with a reduced risk of new dementia diagnoses
Gemma Salvadó • 8 Dec 2025
Gut microbiome as a risk stratification tool and prevention target for neurodegenerative diseases
3:54
Gut microbiome as a risk stratification tool and prevention target for neurodegenerative diseases
Gemma Salvadó • 10 Dec 2025
Microbiome-brain volume associations in cognitively unimpaired adults enriched for AD risk
6:35
Microbiome-brain volume associations in cognitively unimpaired adults enriched for AD risk
Gemma Salvadó • 10 Dec 2025
The potential clinical utility of the novel p-tau205 biomarker in Alzheimer's disease
3:00
The potential clinical utility of the novel p-tau205 biomarker in Alzheimer's disease
Gemma Salvadó • 12 Dec 2025
The content of VJDementia is intended for healthcare professionals